NCT01731652View on ClinicalTrials.gov

Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

February 28, 2014

Study Completion Date

October 31, 2014

Conditions
Carcinoma in SituNon Muscle Invasive Bladder Cancer
Interventions
DRUG

TMX-101

Trial Locations (4)

19004

Urologic Consultants of SE PA, Bala-Cynwyd

29572

Carolina Urologic Research Center, Myrtle Beach

80211

The Urology Center of Colorado, Denver

85032

BCG Oncology, Phoenix

All Listed Sponsors
lead

Telormedix SA

INDUSTRY

NCT01731652 - Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer | Biotech Hunter | Biotech Hunter